Key Highlights

  • Novo Nordisk's Wegovy pill is maintaining a strong lead over Eli Lilly's oral GLP-1 rival in prescription Volume metrics, according to Citi analysts tracking weekly prescription data.
  • The competitive dynamics in the oral obesity medication market are intensifying as both companies attempt to extend their injectable GLP-1 franchises into pill formats that may be more acceptable to a broader patient population.
  • Citi's analysis highlights that Wegovy's Brand-recognition/">Brand Recognition, prescriber familiarity, and patient support infrastructure provide durable commercial advantages beyond the clinical profile of the drug itself.
  • Eli Lilly's oral GLP-1 programme is at an earlier commercial stage, and the prescription gap may narrow significantly as the product gains prescriber familiarity and is supported by increased Marketing Investment.
  • The obesity drug market remains in a very early stage of penetration relative to the estimated patient population that could benefit, meaning both companies have substantial growth runways regardless of relative Market Share dynamics.

 

The Oral GLP-1 Opportunity and Its Scale

The development of oral versions of GLP-1 receptor agonist medications, which have demonstrated transformative efficacy in obesity treatment primarily in injectable formats, represents one of the largest commercial opportunities in pharmaceutical history. Injectables have been the dominant format for GLP-1 therapy since the category emerged, but a significant fraction of patients who could benefit from these medications are unwilling to self-inject, creating a population that is underserved by the current standard of care. If oral formulations can demonstrate efficacy comparable to injectables, the addressable market expands substantially to include patients for whom needle aversion is a barrier to treatment initiation. Both Novo Nordisk and Eli Lilly are pursuing this opportunity aggressively, recognising that the oral market could ultimately be larger than the injectable market that has already generated tens of billions in annual Revenue.

Wegovy's Commercial Infrastructure Advantage

Citi's observation that Wegovy is maintaining its prescription lead reflects something more durable than the drug's clinical profile. Novo Nordisk has built an extraordinary commercial infrastructure around the obesity treatment category, including prescriber education programmes, patient support services, reimbursement navigation assistance, and a brand presence that has made semaglutide the category-defining name for GLP-1 obesity therapy. This infrastructure takes years to build and represents a Competitive Advantage that is not immediately replicable by a company entering the market with a new oral formulation, however strong that formulation's clinical profile. The prescriber who is already comfortable prescribing semaglutide in its injectable form faces a lower cognitive and administrative hurdle in prescribing the oral version than in transitioning to an entirely new molecule.

Eli Lilly's Position and Its Trajectory

Eli Lilly's oral GLP-1 programme, while currently trailing Wegovy in prescription volume, is at an earlier commercial stage and benefits from the same structural advantage that its injectable tirzepatide programme has demonstrated in the market: clinical data showing efficacy that in some studies exceeds that of semaglutide. If the oral tirzepatide data package demonstrates equivalent or superior weight loss outcomes to oral semaglutide, and if Lilly's commercial organisation executes the launch with the quality it has demonstrated in recent product introductions, the current prescription gap is a starting position rather than a permanent competitive outcome. The obesity market is growing fast enough that both companies can gain substantially even as their relative shares evolve.

Reimbursement as the Gating Factor

The most significant constraint on obesity drug market penetration for both Novo Nordisk and Eli Lilly is not competitive but structural: insurance coverage and reimbursement remains inconsistent and often inadequate. Despite the clinical evidence for GLP-1 therapy's efficacy in reducing weight, cardiovascular risk, and associated comorbidities, many private insurers and government payers have been slow to include these medications in formularies at accessible cost-sharing tiers. The Medicare coverage question, which was partially addressed by the Inflation Reduction Act's provisions for certain high-risk patient populations, remains incompletely resolved for the broader obesity indication. The companies' long-term revenue trajectories depend substantially on how quickly and thoroughly reimbursement coverage expands, an outcome that is as much a function of health Economics and lobbying as of clinical development.

The Long-Term Market Penetration Story

Whatever the near-term competitive dynamics between Novo Nordisk and Eli Lilly, the more important analytical frame for long-term investors is the penetration rate of GLP-1 therapy into the estimated population of patients who would benefit clinically. Current penetration rates, even after the explosive growth of the past three years, remain in the single-digit percentages of the clinical addressable market. If reimbursement coverage expands, prescriber comfort with the category increases, Manufacturing capacity constraints ease, and oral formulations bring in the needle-averse population, the category has years of volume growth ahead of it regardless of which company's product is leading in any particular quarter. The competitive story is real and matters for relative returns between the two companies, but the Absolute Return opportunity is driven by category growth rather than share dynamics.